Two cases of interstitial pneumonitis caused by rituximab therapy

Korean Journal of Internal Medicine

Volumn 21, Issue 3, 2006, Pages 183-186

  Lee, Yuna ^a   Kyung, Sun Young ^a   Choi, Soo Jin ^a   Bang, Soo Mee ^a,a   Jeong, Seong Hwan ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Follicular lymphoma; Intestinal pneumonitis; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG RESPONSE; DYSPNEA; FORCED EXPIRATORY VOLUME; HUMAN; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LUNG FUNCTION TEST; LUNG INFILTRATE; LUNG LAVAGE; LYMPH NODE BIOPSY; MALE; NONHODGKIN LYMPHOMA; ORCHIECTOMY; TESTIS TUMOR;

EID: 37849188122     PISSN: 12263303     EISSN: None     Source Type: Journal    
DOI: 10.3904/kjim.2006.21.3.183     Document Type: Article

References (15)

1. Vose JM. Immunotherapy for non-Hodgkin's lymphoma. In: Broudy VC, Abkowitz JL, Vose JM, eds. Hematology, the American Society of Hematology Education Program Book. p. 250-262, 2002
2. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated aggressive non-Hodgkin's lymphoma. J Clin Oncol 19:389-397, 2001
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, van den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235-242, 2002
4. Czuczman MS, Weaver H, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22:4711-4716, 2004
5. Czuczman MS, Koryzna A, Mohr A, Stewart C, Donahue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 23:694-704, 2005
6. UK drug surveillance centre. Roche global drug safety database. 2002
7. Burton C. Kaczmarski R. Jan-Mohamed R. Interstitial peumonitis related to rituximab therapy. N Engl J Med 348:2690-2691, 2003
8. Leon RJ, Gonsalvo A, Salas R, Hidalgo NC. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 79:949-953, 2004
9. Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 81:169-170, 2005
10. Swords R, Power D, Fay M, O'Donnell H, Murphy PT. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 77:103-104, 2004
11. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr, Bearden JD 3rd, Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95:3052-3056, 2000
12. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14:520-535, 2003
13. Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2:378-384, 2001
14. Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 123:2007-2011, 2003
15. Green FH. Overview of pulmonary fibrosis. Chest 122:334S-339S, 2002